Amy Owen-Wyard: A Life Should Not Have a Price Tag Attached to Its Rarity
Amy Owen-Wyard, Director at EquiPath Analytics, Senior Mental Health Nurse at Herefordshire and Worcestershire Health and Care NHS Trust, shared a post on LinkedIn:
“Rare disease innovation is advancing, but only if your condition represents a viable market.
My son lives with Glanzmann Thrombasthenia, an ultra-rare bleeding disorder where platelets don’t function properly.
In the UK, the ‘gold standard’ treatment remains platelet transfusion.
However, repeated transfusions carry a significant risk: antibody development, rendering future transfusions ineffective.
We are now in that position.
The clinical solution offered? Continue using the same approach that increases the risk of complete refractoriness, despite there being no alternative pathway once immunity develops.
This is not a criticism of individual clinicians. It is a systemic failure of prioritisation.
Ultra-rare conditions remain under-researched because they are not commercially attractive.
Meanwhile, families manage significant clinical burden at home, bleeds, monitoring, crisis prevention, much of which is never captured in datasets because it never reaches hospital reporting systems.
If it isn’t recorded, it isn’t counted.
If it isn’t counted, it isn’t prioritised.
That is why we established a research company last year.
Our mission is simple:
- Ensure lived experience sits at the centre of research design and decision-making
- Capture real-world, home-managed data that is currently invisible
- Amplify the voices of families who are too often absent from regulatory and policy conversations
- Influence those with the power to change access, funding and innovation pathways
Equity in healthcare cannot depend on prevalence.
A life should not have a price tag attached to its rarity.
Rare Disease Day raises awareness, but awareness without structural change is not enough.
If you work in research, policy, commissioning, biotech, or regulation and believe patient voice should shape innovation. I would welcome a conversation.”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc
-
Jun 24, 2026, 15:40Annette Bowyer: The Emerging Role of Extravascular Factor VII in Haemostasis
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP